
Product Data Sheet

Product Name: Zonisamide sodium

Cat. No.: GC17952

Chemical Properties

Cas. No. 68291-98-5

Chemical Name sodium;1,2-benzoxazol-3-ylmethylsulfonylzanide

SMILES C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)[NH-].[Na+]

Formula $C_8H_7N_2NaO_3S$ M.Wt 234.21

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Zonisamide sodium is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. Target: Calcium channel inhibitor; Sodium channel inhibitor. Zonisamide sodium is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures for adults; infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide sodium is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. It has shown activity in various animal models of epilepsy, and although a detailed mode of action awaits clarification it appears to block the propagation/spread of seizure discharges and to suppress the epileptogenic focus [1]. Zonisamide sodium 500 mg/day was significantly superior to placebo in reducing the frequency of complex partial seizures (-51% versus -16%), all partial seizures and all seizures, with dose-dependent benefit provided over a 100-500 mg/day dose range. Supporting trials have confirmed significant increases in reduction in median seizure frequency (up to 41%) and responder rates (35-42%)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

compared with placebo following zonisamide sodium 400-600 mg/day, enabling 20-27% of patients to attain $\geq 75\%$ reduction in seizure frequency [2]. Clinical indications: Epilepsy; Lewy body dementia; Parkinsons disease Toxicity: Anorexia; Somnolence; Dizziness; Irritability; Confusional state; Depression; Diplopia; Memory impairment

References:

- [1]. Peters DH, et al. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. *Drugs*. 1993 May;45(5):760-87.
- [2]. Brodie MJ, et al. Zonisamide as adjunctive therapy for refractory partial seizures. *Epilepsy Res*. 2006 Feb;68 Suppl 2:S11-6. Epub 2005 Nov 28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA